Meningococcal ACWY Conjugate Vaccination (MenACWY)
This vaccine is being introduced into the national immunisation programme for England this year to respond to a rapid and accelerating increase in cases of invasive meningococcal group W (MenW) disease, which has been declared a national incident. The MenACWY conjugate vaccine will provide direct protection to the vaccinated cohort and, by reducing MenW carriage, will also provide indirect protection to unvaccinated children and adults. This follows advice from the Joint Committee on Vaccination and Immunisation (JCVI)
We will be offering this vaccination to current school year 13 adolescents who were born between 1.9.1996 and 31.8.1997
Meningococcal ACWY conjugate Vaccination (MenACWY) – for TEENAGERS and YOUNG ADULTS
We will also be offering this vaccination on an opportunistic basis for older first time university entrants up to the age of 25. This is in place of the MenC vaccine.
MenB Immunisation programme
England becomes the first country in the world to begin a national and publicly funded MenB immunisation programme using Bexsero.
On 22 June, the first national, routine, publically-funded MenB vaccination programme in the world was announced with the publication of a joint letter from Public Health England and NHS England. The letter sets out the details of the addition of the new MenB vaccine (Bexsero) to the routine childhood immunisation schedule from 1 September 2015.
Any baby born after 1.5.2015 will receive the vaccine as part of their immunisation schedule.
For more information see www.doh.gov.uk/immunisations or talk to your Health Visitor or one of our Practice Nurses.